Beyond genomics: 3D microtumor assays for rapid, clinically relevant functional drug testing

Area of Science:

• Oncology
• Biotechnology
• Drug Discovery

Background:

• Precision oncology increasingly integrates functional drug testing beyond genomic analysis.
• Genomic sequencing alone often fails to identify effective treatments for rare, resistant, or complex tumors.
• Current limitations hinder personalized therapy selection for a subset of cancer patients.

Purpose of the Study:

• To highlight three-dimensional (3D) microtumor models as an advanced platform for functional drug screening in oncology.
• To demonstrate the capability of 3D microtumor models in preserving native tumor architecture and microenvironment.
• To showcase the potential of 3D models in overcoming limitations of 2D cultures and genomics for predicting therapeutic response.

Main Methods:

• Utilizing three-dimensional (3D) microtumor models derived from patient tumors.
• Preserving tumor architecture, cellular composition, and microenvironmental factors within the 3D models.
• Performing drug screening assays on these 3D microtumor models to assess therapeutic efficacy.

Main Results:

• 3D microtumor models successfully recapitulate key aspects of intact tumor biology.
• These models capture biological responses to therapies that are missed by 2D models and genomic data.
• The approach demonstrates enhanced accuracy in predicting therapeutic vulnerabilities.

Conclusions:

• Three-dimensional (3D) microtumor models represent a significant advancement in functional drug screening for precision oncology.
• This technology expands the precision oncology toolkit, offering new therapeutic options for patients with difficult-to-treat cancers.
• By integrating functional testing, 3D microtumor models improve the prediction of treatment effectiveness, especially for genomically ambiguous or resistant tumors.